Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Projected Market Size and Growth Rates for the Human Metapneumovirus (hMPV) Therapeutics Market From 2025 To 2029?
In recent years, there has been robust growth in the human metapneumovirus (hmpv) therapeutics market size. It is expected to increase from $0.66 billion in 2024 to $0.7 billion in 2025, with a compound annual growth rate (CAGR) of 5.7%. Factors contributing to the growth during the historic period include enhanced understanding of viral respiratory infections, higher occurrence of pediatric respiratory diseases, increased rates of hospitalisation, global efforts to improve health monitoring, and a growing concentration on research into newly developing respiratory viruses.
The market for therapeutics centered on the human metapneumovirus (hmpv) is projected to experience substantial expansion in the years to come. The market will surge to a worth of$0.89 billion by 2029, displaying a compound annual growth rate (CAGR) of 6.1%. The growth during this period is expected to be fueled by an uplifted demand for supplemental treatments, an increase in financial support from government bodies and NGOs, amplified awareness about respiratory infections, an increase in pediatric respiratory disease occurrences, and a burgeoning demand for precise therapies. The market is anticipated to be characterized by trends such as the integration of technology into diagnostic systems, technological progression in the creation of antiviral drugs, advancements in research towards vaccine development and delivery processes, point-of-care testing guided by technology, and progression in molecular diagnostics.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23420&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Human Metapneumovirus (hMPV) Therapeutics Market?
The surge in cases of respiratory infections is anticipated to spark a growth in the human metapneumovirus (HMPV) therapeutics market. Respiratory infections, which affect the nose, throat, airways and lungs, are on the rise due to increasing levels of air pollution. These pollutants such as particulate matter and nitrogen dioxide, irritate and compromise the respiratory tract, making people more prone to infections. Therapies for Human metapneumovirus (hMPV) are vital for managing these infections by limiting viral replication and inflammation via antiviral treatments and supportive care, enhancing health prospects for high-risk groups like infants, the elderly, and those with weakened immune systems. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency based in Australia, reported that Chronic Obstructive Pulmonary Disease (COPD) in Australia represented 3.6% of the total disease burden in 2023. It attributed to 50% of the overall load from respiratory conditions, with approximately 638,000 individuals (2.5% of the population) dealing with COPD in 2022. Consequently, the escalating prevalence of respiratory infections propels growth in the human metapneumovirus (HMPV) therapeutics market.
Which Key Market Segments Comprise the Human Metapneumovirus (hMPV) Therapeutics Market and Drive Its Revenue Growth?
The human metapneumovirus (hmpv) therapeuticsmarket covered in this report is segmented –
1) By Drug Class: Antipyretic; Decongestants; Cough Suppressants; Other Drug Class
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End-Use: Hospitals And Clinics; Diagnostic And Reference Laboratories; Academic And Research Institutions; Other End-Uses
Subsegments:
1) By Antipyretic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Acetaminophen (Paracetamol)
2) By Decongestants: Nasal Decongestants, Oral Decongestants
3) By Cough Suppressants: Dextromethorphan, Codeine, Benzonatate
4) By Other Drug Class: Antiviral Agents, Antibiotics (if secondary bacterial infection occurs), Inhaled Corticosteroids
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=23420&type=smp
Which Areas Are Leading Regions in the Human Metapneumovirus (hMPV) Therapeutics Market Expansion Across the Globe?
North America was the largest region in the human metapneumovirus (hMPV) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human metapneumovirus (hMPV) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in theHuman Metapneumovirus (hMPV) Therapeutics Market Over the Coming Years?
Prominent firms in the human metapneumovirus (hMPV) therapeutics domain are intensifying their efforts to formulate specialised antiviral treatments like monoclonal antibodies to tackle hMPV infections effectively. Monoclonal antibodies are bio-engineered proteins designed to simulate the immune system’s inherent disease-fighting capabilities. They offer precision treatment for a wide range of illnesses, including cancer and autoimmune diseases, by latching onto and neutralising detrimental antigens or cells. For instance, a UK-based biopharmaceutical company called Vicebio Ltd. managed to secure a Series B financing of $100 million in October 2024. TCGX led the funding round, with considerable contributions from Goldman Sachs Alternatives and other participants. The funds will propel the Phase 1 clinical trial of VXB-241, a dual-action vaccine targeting both RSV and hMPV, with preliminary outcomes expected by mid-2025. Additionally, it will expedite the formulation of VXB-251, a three-pronged vaccine designed to combat RSV, hMPV, and Parainfluenza Virus 3, to tackle notable health issues in the elderly population.
View the full report here:
How Is the Human Metapneumovirus (hMPV) Therapeutics Market Conceptually Defined?
Human metapneumovirus (hMPV) therapeutics refers to the medical treatments and interventions aimed at managing and alleviating the symptoms caused by human metapneumovirus, a respiratory virus that commonly affects infants, older people, and immunocompromised individuals. The therapeutics work by inhibiting viral replication, blocking viral entry into host cells, and modulating the immune response to reduce inflammation and disease severity.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23420
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
